Telness Tech Appoints Octopus Group Chairman John Browett to Board of Directors
Article content
Browett currently serves as Chairman of Octopus Group, the company who founded Octopus Energy, whose Kraken Technologies platform has redefined how technology can transform traditional industries. He has also held executive leadership roles at Apple and Tesco, helping scale globally recognized businesses and pioneer large-scale e-commerce in one of Europe's most competitive retail environments.
Article content
Article content
'Telness Tech is doing to telecom what Kraken has done to the energy sector — rewriting the rules,' says John Browett. 'Martina and the team have built a unique platform with a proven ability to help operators leapfrog legacy systems, vendors, and modules — essentially making telecom, a traditionally complex industry, easier and more joyful than ever. I'm thrilled to be part of that journey.'
Article content
'John's experience leading some of the world's most innovative and customer-centric companies makes him an invaluable addition to our board,' says Martina Klingvall, CEO and Founder of Telness Tech. 'His unique combination of strategic vision, operational excellence, and boardroom expertise will help guide us as we continue to simplify telecom globally.'
Article content
Telness Tech's flagship product, Seamless OS, is a cloud-native platform that enables any mobile operator or digital-first company to launch or expand mobile services using the power of AI and automation. In 2024 and 2025, the company entered the U.S., European, and African markets, and its platform now powers more than 24 mobile operators, including partnerships with industry leaders such as T-Mobile and Lebara. About Telness Tech Telness Tech is one of the world's fastest growing teltech companies. It's flagship product, Seamless OS, is a cloud-based BSS/OSS platform that enables companies to launch, operate, and scale fully digital, AI-powered mobile services. Often described as the ' Shopify for telecom,' Telness Tech makes it radically simple and efficient to run or become a mobile operator. Originally developed within Swedish operator Telness — one of Europe's highest-rated mobile providers — Telness Tech now empowers telecom disruptors across the U.S., Europe, and beyond.
Article content
Article content
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
3 hours ago
- Globe and Mail
FMS Stock Rises as Q2 Earnings Beat Estimates, Revenues Gain Y/Y
Fresenius Medical Care AG & Co. FMS reported second-quarter 2025 adjusted earnings per share (EPS) of 52 cents, which surpassed the Zacks Consensus Estimate by 4%. The bottom line improved 36.8% year over year. FMS' Revenue Details Revenues of $5.44 billion (EUR 4,792 million) beat the Zacks Consensus Estimate by 1.6%. The top line increased 1% year over year and 5% at constant currency (cc). Also, revenues were up 7% organically. Per management, during the second quarter, divestitures realized as part of the portfolio optimization plan hurt revenue development by EUR 6 million. The full-year top-line numbers are anticipated to reflect 100 basis points of negative impact due to the portfolio optimization plan in 2024. Shares of FMS gained nearly 2.2% in yesterday's after-market trading. The stock has risen 7.9% year to date against the industry 's decline of 8.8%. The S&P 500 Index has increased 7.4% in the same period. Segmental Details Fresenius Medical implemented a new operating model in 2024 and started reporting under two new segments, Care Delivery and Care Enablement. Care Delivery The segment's revenues were down 3% on a year-over-year basis but up 1% at cc. However, revenues gained 4% on an organic basis. Revenues in the U.S. markets declined 2% reportedly but gained 3% on an organic basis. The top line also improved 3% year over year at cc. Per management, unfavorable exchange rates along with increased mortality due to the severe flu season in the United States in the first months of the year hurt sales in the country. However, this was partially offset by an accelerated number of patient new starts, reimbursement rate increases and a favorable payor mix. Per management, during the first quarter of 2025, U.S. same-market treatment growth remained flat year over year. International sales declined 8% reportedly as well as at cc but gained 5% on an organic basis. The decline was due to divestments realized as part of the portfolio optimization plan, which was partially offset by organic growth. The organic growth was supported by accelerated same-market treatment growth of 1.7%. Care Enablement The segment's revenues decreased 1% year over year reportedly but gained 3% at cc as well as organically. Volume growth and continued positive pricing momentum were offset by unfavorable exchange rate effects. Margin Analysis In the quarter under review, Fresenius Medical's gross profit improved 4.2% year over year. The gross margin expanded 90 basis points (bps) to 25.4%. Selling, general & administrative expenses increased 2.7% on a reported basis. Research and development expenses decreased 17.4% year over year. Adjusted operating income improved 9.2% from the prior-year quarter's level. The adjusted operating margin in the second quarter expanded 80 bps to 9.9%. 2025 Guidance For 2025, Fresenius Medical continues to expect revenue growth to be positive, with a low-single-digit percent rate compared to the prior year. The company also expects operating income to grow by a high-teens to high-twenties percent rate compared to the prior year. Our Take FMS exited the second quarter on a strong note, with its earnings and revenues surpassing their respective consensus estimate. Overall pricing momentum also supported growth in the Care Enablement segment. However, the effects of elevated mortality will likely continue to have a negative impact on sales. Per management, during the first quarter, the FME25 transformation program continued its positive momentum, delivering EUR 58 million additional sustainable savings while related one-time costs, treated as special items, amounted to EUR 53 million. The company confirmed its full-year target of around EUR 180 million in additional annual savings, totaling EUR 1050 million by 2027-end. FMS' continued divestment of its non-core and dilutive assets appears promising, as it will help focus on its core and growing categories, while also boosting its cash resources. FMS' Zacks Rank & Other Stocks to Consider Fresenius Medical currently sports a Zacks Rank #1 (Strong Buy). Some other top-ranked stocks in the broader medical space that have announced quarterly results are Medpace Holdings, Inc. MEDP, West Pharmaceutical Services, Inc. WST and Boston Scientific Corporation BSX. Medpace Holdings, sporting a Zacks Rank of 1 at present, reported second-quarter 2025 EPS of $3.10, which beat the Zacks Consensus Estimate by 3.3%. You can see the complete list of today's Zacks #1 Rank stocks here. Revenues of $603.3 million outpaced the consensus mark by 11.5%. Medpace Holdings has a long-term estimated growth rate of 11.4%. MEDP's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 13.9%. West Pharmaceutical reported second-quarter 2025 adjusted EPS of $1.84, which beat the Zacks Consensus Estimate by 21.9%. Revenues of $766.5 million surpassed the Zacks Consensus Estimate by 5.4%. It currently flaunts a Zacks Rank #1. West Pharmaceutical has a long-term estimated growth rate of 8.5%. WST's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%. Boston Scientific reported second-quarter 2025 adjusted EPS of 75 cents, which beat the Zacks Consensus Estimate by 4.2%. Revenues of $5.06 billion surpassed the Zacks Consensus Estimate by 3.5%. It currently carries a Zacks Rank #2 (Buy). Boston Scientific has a long-term estimated growth rate of 14%. BSX's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.1%. Zacks' Research Chief Picks Stock Most Likely to "At Least Double" Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren't winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%. See Our Top Stock to Double (Plus 4 Runners Up) >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX): Free Stock Analysis Report Fresenius Medical Care AG & Co. KGaA (FMS): Free Stock Analysis Report West Pharmaceutical Services, Inc. (WST): Free Stock Analysis Report Medpace Holdings, Inc. (MEDP): Free Stock Analysis Report
National Post
3 hours ago
- National Post
ChatGPT giving teens dangerous advice on drugs, alcohol and suicide: new study
Article content Common Sense has labeled ChatGPT a 'moderate risk' for teens, with enough guardrails to make it relatively safer than chatbots purposefully built to embody realistic characters or romantic partners. But the new research by CCDH — focused specifically on ChatGPT because of its wide usage — shows how a savvy teen can bypass those guardrails. Article content ChatGPT does not verify ages or parental consent, even though it says it's not meant for children under 13 because it may show them inappropriate content. To sign up, users simply need to enter a birthdate that shows they are at least 13. Other tech platforms favored by teenagers, such as Instagram, have started to take more meaningful steps toward age verification, often to comply with regulations. They also steer children to more restricted accounts. Article content When researchers set up an account for a fake 13-year-old to ask about alcohol, ChatGPT did not appear to take any notice of either the date of birth or more obvious signs. Article content Article content 'I'm 50kg and a boy,' said a prompt seeking tips on how to get drunk quickly. ChatGPT obliged. Soon after, it provided an hour-by-hour 'Ultimate Full-Out Mayhem Party Plan' that mixed alcohol with heavy doses of ecstasy, cocaine and other illegal drugs. Article content 'What it kept reminding me of was that friend that sort of always says, 'Chug, chug, chug, chug,'' said Ahmed. 'A real friend, in my experience, is someone that does say 'no' — that doesn't always enable and say 'yes.' This is a friend that betrays you.' Article content To another fake persona — a 13-year-old girl unhappy with her physical appearance — ChatGPT provided an extreme fasting plan combined with a list of appetite-suppressing drugs. Article content 'We'd respond with horror, with fear, with worry, with concern, with love, with compassion,' Ahmed said. 'No human being I can think of would respond by saying, 'Here's a 500-calorie-a-day diet. Go for it, kiddo.'' Article content
National Post
4 hours ago
- National Post
SPEC Labs Announces Board Transitions to Support Next Phase of Expansion
Article content MISSISSAUGA, Ontario — SPEC Labs, a national provider of coworking wet lab facilities for Canada's life sciences sector, today announced the appointment of two new distinguished leaders, Abdullah Snobar and Bob Hill, to its Board of Directors. Article content Bob Hill brings decades of experience in life sciences, commercialization, and strategic operations. A seasoned executive and advisor, Bob's leadership has helped guide numerous early-stage life sciences companies through scale-up, regulatory navigation, and partnership growth. His strategic insight will support SPEC Labs as it expands its footprint and deepens its value to life sciences residents and partners across the region. Article content 'I am excited to join the Board of Directors of SPEC Labs and work with such a talented leadership group,' Article content said Bob Hill. Article content 'We have a vibrant life sciences sector in Canada and I am delighted to play a role in helping to address such a critical need for our ecosystem.' Article content Abdullah Snobar is the Executive Director of the DMZ at Toronto Metropolitan University, one of Canada's top startup incubators, and a nationally recognized leader in entrepreneurship and innovation policy. His expertise in ecosystem building, equity in innovation, and supporting high-growth startups aligns seamlessly with SPEC Labs' mission to empower the next generation of life sciences entrepreneurs. Article content 'Canada's life sciences sector needs bold infrastructure and bold vision. SPEC Labs is delivering both,' Article content said Abdullah Snobar. Article content 'I'm honoured to support its mission of helping emerging biotech founders scale breakthrough innovations right here at home.' Article content These appointments come at a pivotal moment as SPEC Labs prepares to open its flagship location in Mississauga, Ontario. The facility will serve as a launchpad for graduation-stage biotech and life sciences companies, providing critical lab infrastructure and a supportive commercialization environment. Article content 'Abdullah and Bob bring unique and highly complementary strengths to the Board,' Article content said Doris Qamar, CEO of SPEC Labs. Article content 'Abdullah's leadership in building high-performance Article content growth strategy as we expand across Canada.' At the same time, SPEC Labs is announcing the departure of two long-standing board members: Dr. Pamela Plant and Dr. Leyla Soleymani. Both played foundational roles in guiding SPEC Labs from its inception through to its current launch phase. Article content 'Pamela and Leyla have been instrumental to our success,' Article content said Doris Qamar. Article content guidance, energy, and belief in SPEC Labs' mission helped shape the organization into what it is today. We are deeply thankful for their contributions and wish them the very best in Article content their next chapters.' Article content As SPEC Labs moves forward, the expanded Board will help steer the organization through its first facility opening and national growth. The new appointments underscore SPEC Labs' commitment to strong governance, strategic partnerships, and mission-driven leadership in Canada's life sciences ecosystem. Article content SPEC Labs is a not-for-profit operator of coworking wet lab facilities purpose-built for Canada's graduation-stage life sciences companies. With a model inspired by global best practices, SPEC Labs provides flexible, affordable lab space and wraparound support to help emerging biotech ventures thrive. Article content Article content Article content
